Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2009-017333-21 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this observational study is to broaden the knowledge of the known safety and efficacy profile of Keppra® (Levetiracetam) oral solution in epileptic infants younger than 12 months when treated according to routine clinical practice. Their data will be collected until they reach the age of 13 months.
This non-interventional sentinel sites post-authorization safety study (PASS) aims to collect additional data on use of Keppra® (Levetiracetam) oral solution in clinical practice, and on efficacy and safety of Keppra® (Levetiracetam) in infants younger than12 months. Epileptic patients between the age of 1 month and 11 months inclusive can be invited for participation to the non-interventional sentinel sites PASS, after the physician has decided to initiate therapy with Keppra® (Levetiracetam) oral solution (100 mg/ml bottle) and patient has so far been treated with Keppra® (Levetiracetam) for no longer than 10 days. The patients will be followed and their data will be collected until they reach the age of 13 months.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients, 1 - 11 months old, prescribed Keppra® oral solution | Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who are between 1 and 11 months old. The patients will be followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, is made independently by the physician in the regular course of practice and is not influenced by the study protocol. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Safety Follow-up Visit | Number of patients with any Treatment-Emergent Adverse Events (TEAEs) as reported by the patient's parent and/or caregiver or observed by the treating physician during the study (maximum Treatment Period is 12 months plus 2-week safety follow-up). | From Baseline through the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-week safety follow-up) |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Overall Serious Treatment-Emergent Adverse Events (TEAEs) From Baseline Through the Safety Follow-up | Number of patients with any serious Treatment-Emergent Adverse Events (TEAEs) during the study (maximum Treatment Period is 12 months plus 2-week safety follow-up). | From Baseline through the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-weeks safety follow-up) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients coming to day clinic for consultation by specialist
Not provided
| Name | Affiliation | Role |
|---|---|---|
| UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 012 | Amiens | France | ||||
| 010 |
Not provided
| Label | URL |
|---|---|
| FDA safety Alerts and Recalls | View source |
Not provided
Overall 101 patients were enrolled. The Participant Flow refers to the Enrolled Set (ES). The ES consisted of patients with a signed Data Consent Form.
It was planned to enroll 100 patients at approximately 30-40 sites in the European Union.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Patients, 1 - 11 Months Old, Prescribed Keppra® Oral Solution | Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who were between 1 and 11 months old. The patients were followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, was made independently by the physician in the regular course of practice and was not influenced by the study protocol. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
| Incidence of Treatment-Emergent Adverse Events (TEAEs) Leading to Temporary or Permanent Discontinuation of Keppra® (Levetiracetam) From Baseline Through the Last Visit | Number of patients with any Treatment-Emergent Adverse Events (TEAEs) leading to temporary or permanent discontinuation of Keppra® (Levetiracetam) during the Treatment Period (maximum 12 months). | From Baseline through the last Treatment Visit (maximum 12 months) |
| Presence of Deviation From the Normal Milestones of Psychomotor Development From Baseline to the Last Treatment Visit | Number of patients with presence of deviation from the normal milestones of psychomotor development during the Treatment Period (maximum 12 months). The treating physician evaluated at each visit, as part of standard clinical practice, the psychomotor development of the patient. The evaluation of the patient's psychomotor development was categorized by the motor development, the social development and the language development. | From Baseline to the last Treatment Visit (maximum 12 months) |
| Mean Change From Baseline in Standardized Body Weight Scores at the Safety Follow-up Visit | For each visit, body weight was measured and standardization for gender and age was performed based on WHO growth charts to obtain z-scores. For this outcome measure, the mean of the differences of individual body weight z-scores from Safety Follow-up Visit to Baseline was determined. | From Baseline to the safety follow-up visit (maximum treatment period is 12 months plus 2-week safety follow-up) |
| Mean Change From Baseline in Standardized Body Length Scores at the Safety Follow-up Visit | For each visit, body length was measured and age standardization was performed based on WHO growth charts to obtain z-scores. For this outcome measure, the difference of body length z-scores from Safety Follow-up Visit to Baseline was determined and averaged across the study population. | From Baseline to the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-week safety follow-up) |
| Mean Change From Baseline in Standardized Head Circumference Scores at the Safety Follow-up Visit | For each visit, head circumference was measured and age standardization was performed based on WHO growth charts to obtain z-scores. For this outcome measure, the difference of head circumference z-scores from Safety Follow-up Visit to Baseline was determined and averaged across the study population. | From Baseline to the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-week safety follow-up) |
| Number of Patients With Abnormalities Noted During Physical Examination From Baseline to the Last Treatment Visit | Number of patients with abnormalities noted during physical examination over the Treatment Period (maximum 12 months). Any abnormal findings during the physical examination during the study were reported as Adverse Events (AEs). The Number of Patients With Abnormalities Noted During Physical Examination From Baseline to the Last Treatment Visit cannot be given because abnormalities at Screening are listed only and worsening after Screening were handled as AEs and tabulated along with the other AEs. | From Baseline to the last Treatment Visit (maximum 12 months) |
| Number of Patients With Abnormalities Noted During Neurological Examination From Baseline to the Last Treatment Visit | The Number of Patients With Abnormalities Noted During Neurological Examination cannot be given because abnormality frequencies were only determined for single parameters of the neurological examination and therefore a subject might have been counted several times. | From Baseline to the last Treatment Visit (maximum 12 months) |
| Global Evaluation Scale of the Psychomotor Development (GES) | Global evaluation scale of the psychomotor development (GES): physician's assessment of the change from Baseline in the psychomotor development at the last Treatment Visit (maximum timeframe is 12 months). The GES is a 7-point scale with the following options: 7=Marked improvement 6=Moderate improvement 5=Slight improvement 4=No Change 3=Slight worsening 2=Moderate worsening 1=Marked worsening As a variant of this variable, a 3-class variable was derived as follows
| From Baseline to the last Treatment Visit (maximum 12 months) |
| Global Evaluation Scale of Epilepsy Severity (GES) | Global evaluation scale of epilepsy severity (GES): physician's assessment of the change from Baseline of the epilepsy severity at the last Treatment Visit (maximum 12 months). The GES is a 7-point scale that assesses change in the severity of the patient's illness. The GES is a 7-point scale with the following options: 7=Marked improvement 6=Moderate improvement 5=Slight improvement 4=No Change 3=Slight worsening 2=Moderate worsening 1=Marked worsening As a variant of this variable, a 3-class variable was derived as follows
| From Baseline to the last Treatment Visit (maximum time frame is 12 months) |
| Number of Patients Who Withdraw Due to Lack or Loss of Efficacy During the Treatment Period | Number of patients who withdraw due to lack or loss of efficacy during the Treatment Period (maximum 12 months). | From Baseline through the last Treatment Visit (maximum 12 months) |
| Bron |
| France |
| 011 | Paris | France |
| 027 | Berlin | Germany |
| 024 | Bielefeld | Germany |
| 026 | Heidelberg | Germany |
| 021 | Kehl Kork | Germany |
| 023 | Kiel | Germany |
| 022 | Münster | Germany |
| 072 | Athens | Greece |
| 071 | Pátrai | Greece |
| 037 | Bologna | Italy |
| 031 | Calambrone | Italy |
| 032 | Milan | Italy |
| 034 | Roma | Italy |
| 035 | Verona | Italy |
| 065 | Gdansk | Poland |
| 064 | Lodz | Poland |
| 063 | Szczecin | Poland |
| 062 | Warsaw | Poland |
| 043 | Barcelona | Spain |
| 044 | Madrid | Spain |
| 045 | Madrid | Spain |
| 046 | Murcia | Spain |
| 057 | Birmingham | United Kingdom |
| 052 | Liverpool | United Kingdom |
| 051 | London | United Kingdom |
| COMPLETED |
|
| NOT COMPLETED |
|
|
The Baseline Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Patients, 1 - 11 Months Old, Prescribed Keppra® Oral Solution | Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who were between 1 and 11 months old. The patients were followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, was made independently by the physician in the regular course of practice and was not influenced by the study protocol. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | months |
| ||||||||||||||||||||||
| Age, Customized | Number | participants |
| |||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Weight | Mean | Standard Deviation | kilogram |
| ||||||||||||||||||||||
| Height | Mean | Standard Deviation | centimeter |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Treatment-Emergent Adverse Events (TEAEs) From Baseline Through Safety Follow-up Visit | Number of patients with any Treatment-Emergent Adverse Events (TEAEs) as reported by the patient's parent and/or caregiver or observed by the treating physician during the study (maximum Treatment Period is 12 months plus 2-week safety follow-up). | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. | Posted | Number | participants | From Baseline through the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-week safety follow-up) |
|
|
| ||||||||||||||||||||||||||
| Secondary | Incidence of Overall Serious Treatment-Emergent Adverse Events (TEAEs) From Baseline Through the Safety Follow-up | Number of patients with any serious Treatment-Emergent Adverse Events (TEAEs) during the study (maximum Treatment Period is 12 months plus 2-week safety follow-up). | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. | Posted | Number | participants | From Baseline through the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-weeks safety follow-up) |
|
| |||||||||||||||||||||||||||
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) Leading to Temporary or Permanent Discontinuation of Keppra® (Levetiracetam) From Baseline Through the Last Visit | Number of patients with any Treatment-Emergent Adverse Events (TEAEs) leading to temporary or permanent discontinuation of Keppra® (Levetiracetam) during the Treatment Period (maximum 12 months). | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. | Posted | Number | participants | From Baseline through the last Treatment Visit (maximum 12 months) |
|
| |||||||||||||||||||||||||||
| Secondary | Presence of Deviation From the Normal Milestones of Psychomotor Development From Baseline to the Last Treatment Visit | Number of patients with presence of deviation from the normal milestones of psychomotor development during the Treatment Period (maximum 12 months). The treating physician evaluated at each visit, as part of standard clinical practice, the psychomotor development of the patient. The evaluation of the patient's psychomotor development was categorized by the motor development, the social development and the language development. | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. Presented is the number of subjects with non-missing data on psychomotor development at the corresponding visit. | Posted | Number | participants | From Baseline to the last Treatment Visit (maximum 12 months) |
|
| |||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Standardized Body Weight Scores at the Safety Follow-up Visit | For each visit, body weight was measured and standardization for gender and age was performed based on WHO growth charts to obtain z-scores. For this outcome measure, the mean of the differences of individual body weight z-scores from Safety Follow-up Visit to Baseline was determined. | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. | Posted | Mean | Standard Deviation | z-scores | From Baseline to the safety follow-up visit (maximum treatment period is 12 months plus 2-week safety follow-up) |
|
| ||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Standardized Body Length Scores at the Safety Follow-up Visit | For each visit, body length was measured and age standardization was performed based on WHO growth charts to obtain z-scores. For this outcome measure, the difference of body length z-scores from Safety Follow-up Visit to Baseline was determined and averaged across the study population. | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. | Posted | Mean | Standard Deviation | z-scores | From Baseline to the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-week safety follow-up) |
|
| ||||||||||||||||||||||||||
| Secondary | Mean Change From Baseline in Standardized Head Circumference Scores at the Safety Follow-up Visit | For each visit, head circumference was measured and age standardization was performed based on WHO growth charts to obtain z-scores. For this outcome measure, the difference of head circumference z-scores from Safety Follow-up Visit to Baseline was determined and averaged across the study population. | The Analysis Population refers to the Safety Set (SS). The SS consisted of all patients in the Enrolled Set who received at least 1 (partial) dose of study medication. | Posted | Mean | Standard Deviation | z-scores | From Baseline to the Safety Follow-up Visit (maximum Treatment Period is 12 months plus 2-week safety follow-up) |
|
| ||||||||||||||||||||||||||
| Secondary | Number of Patients With Abnormalities Noted During Physical Examination From Baseline to the Last Treatment Visit | Number of patients with abnormalities noted during physical examination over the Treatment Period (maximum 12 months). Any abnormal findings during the physical examination during the study were reported as Adverse Events (AEs). The Number of Patients With Abnormalities Noted During Physical Examination From Baseline to the Last Treatment Visit cannot be given because abnormalities at Screening are listed only and worsening after Screening were handled as AEs and tabulated along with the other AEs. | Not Posted | From Baseline to the last Treatment Visit (maximum 12 months) | ||||||||||||||||||||||||||||||||
| Secondary | Number of Patients With Abnormalities Noted During Neurological Examination From Baseline to the Last Treatment Visit | The Number of Patients With Abnormalities Noted During Neurological Examination cannot be given because abnormality frequencies were only determined for single parameters of the neurological examination and therefore a subject might have been counted several times. | Not Posted | From Baseline to the last Treatment Visit (maximum 12 months) | ||||||||||||||||||||||||||||||||
| Secondary | Global Evaluation Scale of the Psychomotor Development (GES) | Global evaluation scale of the psychomotor development (GES): physician's assessment of the change from Baseline in the psychomotor development at the last Treatment Visit (maximum timeframe is 12 months). The GES is a 7-point scale with the following options: 7=Marked improvement 6=Moderate improvement 5=Slight improvement 4=No Change 3=Slight worsening 2=Moderate worsening 1=Marked worsening As a variant of this variable, a 3-class variable was derived as follows
| The Analysis Population refers to the Full Analysis Set (FAS). The FAS consisted of all patients in the Enrolled Set who had at least 1 post-Baseline efficacy assessment. Presented is the number of subjects with a non-missing measurement at Visit 7. | Posted | Number | participants | From Baseline to the last Treatment Visit (maximum 12 months) |
| ||||||||||||||||||||||||||||
| Secondary | Global Evaluation Scale of Epilepsy Severity (GES) | Global evaluation scale of epilepsy severity (GES): physician's assessment of the change from Baseline of the epilepsy severity at the last Treatment Visit (maximum 12 months). The GES is a 7-point scale that assesses change in the severity of the patient's illness. The GES is a 7-point scale with the following options: 7=Marked improvement 6=Moderate improvement 5=Slight improvement 4=No Change 3=Slight worsening 2=Moderate worsening 1=Marked worsening As a variant of this variable, a 3-class variable was derived as follows
| The Analysis Population refers to the Full Analysis Set (FAS). The FAS consisted of all patients in the Enrolled Set who had at least 1 post-Baseline efficacy assessment. Presented is the number of subjects with a non-missing measurement at Visit 7. | Posted | Number | participants | From Baseline to the last Treatment Visit (maximum time frame is 12 months) |
| ||||||||||||||||||||||||||||
| Secondary | Number of Patients Who Withdraw Due to Lack or Loss of Efficacy During the Treatment Period | Number of patients who withdraw due to lack or loss of efficacy during the Treatment Period (maximum 12 months). | The Analysis Population refers to the Full Analysis Set (FAS). The FAS consisted of all patients in the Enrolled Set who had at least 1 post-Baseline efficacy assessment. | Posted | Number | participants | From Baseline through the last Treatment Visit (maximum 12 months) |
|
|
Treatment emergent Adverse Events (TEAEs) were reported from Baseline through the Safety Follow-up Visit.
Treatment emergent Adverse Events (AEs) are AEs with onset date (including severity-worsening) on or after first dose of study medication.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Patients, 1 - 11 Mths Old, Prescribed Keppra® Oral Solution | Epileptic patients who have been prescribed Keppra® (Levetiracetam) oral solution and who were between 1 and 11 months old. The patients were followed as per current clinical practices for their condition. The choice of medical treatment, including the concomitant use of other antiepileptic drugs, was made independently by the physician in the regular course of practice and was not influenced by the study protocol. | 32 | 101 | 19 | 101 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | 16.1 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | 16.1 | Non-systematic Assessment |
| |
| Drug withdrawal syndrome | General disorders | 16.1 | Non-systematic Assessment |
| |
| Pyrexia | General disorders | 16.1 | Non-systematic Assessment |
| |
| Bronchiolitis | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Gastroenteritis | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Lower respiratory tract infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Candida infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Device related infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Gastroenteritis viral | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Lung infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Otitis media | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Pneumonia viral | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Upper respiratory tract infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Viral infection | Infections and infestations | 16.1 | Non-systematic Assessment |
| |
| Gastrointestinal stoma complication | Injury, poisoning and procedural complications | 16.1 | Non-systematic Assessment |
| |
| Lower limb fracture | Injury, poisoning and procedural complications | 16.1 | Non-systematic Assessment |
| |
| Convulsion | Nervous system disorders | 16.1 | Non-systematic Assessment |
| |
| Epilepsy | Nervous system disorders | 16.1 | Non-systematic Assessment |
| |
| Hydrocephalus | Nervous system disorders | 16.1 | Non-systematic Assessment |
| |
| Hyperkinesia | Nervous system disorders | 16.1 | Non-systematic Assessment |
| |
| Infantile spasms | Nervous system disorders | 16.1 | Non-systematic Assessment |
| |
| Status epilepticus | Nervous system disorders | 16.1 | Non-systematic Assessment |
| |
| Inappropriate affect | Psychiatric disorders | 16.1 | Non-systematic Assessment |
| |
| Sleep disorder | Psychiatric disorders | 16.1 | Non-systematic Assessment |
| |
| Respiratory disorder | Respiratory, thoracic and mediastinal disorders | 16.1 | Non-systematic Assessment |
| |
| Respiratory distress | Respiratory, thoracic and mediastinal disorders | 16.1 | Non-systematic Assessment |
| |
| Apnoea | Respiratory, thoracic and mediastinal disorders | 16.1 | Non-systematic Assessment |
| |
| Bronchial obstruction | Respiratory, thoracic and mediastinal disorders | 16.1 | Non-systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | 16.1 | Non-systematic Assessment |
| |
| Neurosurgery | Surgical and medical procedures | 16.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Diarrhoea | Gastrointestinal disorders | 16.1 | Non-systematic Assessment |
| |
| Pyrexia | General disorders | 16.1 | Non-systematic Assessment |
| |
| Bronchitis | Infections and infestations | 16.1 | Non-systematic Assessment |
|
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| UCB Cares | UCB | +1 877 822 9493 |
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ≥6 - ≤11 months |
|
| >11 months |
|
|
|
| Participants |
|
|
|
|
|
| Units | Counts |
|---|---|
| Participants |
|
|
|
|
|